Mylan Wins Right To Acquire Merck KGaA Generics Business For $6.7 Billion
This article was originally published in The Pink Sheet Daily
Executive Summary
Global footprint will allow U.S. generics firm to maximize its follow-on biologics strategy, CEO Coury says.
You may also be interested in...
Three Largest U.S. Generic Firms See Diversification As Best Path Through Reverse Patent Cliff
Expanded technological capabilities, narrowed focus on alternative dosage forms and harder-to-replicate products, and growing international reach are among the strategies being employed by Teva, Mylan and Watson in the face of 2013’s anticipated reverse patent cliff.
Despite Stock Price Volatility, Mylan’s Upside Attractive
Firm expects two new launches this fall, CEO Coury says.
Despite Stock Price Volatility, Mylan’s Upside Attractive
Firm expects two new launches this fall, CEO Coury says.